Sanofi-aventis becomes a major partner in the biotechnology field in year leading to BIO 2008
Sanofi-aventis becomes a major partnerin the biotechnology fieldin year leading to BIO 2008With nine major agreements concluded in the last twelve months, sanofi-aventis is a partner of choiceto develop molecules & vaccines for the futureSan Diego, California - June 17, 2008 - Sanofi-aventis announced today at the Biotechnology Industry Organization (BIO) 2008 International Convention that three new therapeutic antibodies and six new vaccines in development are stemming from agreements signed in the past year. The therapeutic antibodies target inflammatory or oncology indications.